Welfare and quality of farmed trout fed high plant protein diets. 1 Growth performance and quality traits

AbstractThis study was performed to evaluate the effects of high levels of inclusion of plant protein sources to replace fish meal in rainbow trout (O. mykiss) diets on growth performance and quality characteristics. Two isoproteic (44.8%) and isolipidic (19.6%) extruded diets were fed to eight groups of trout (IBW 106.6g) for 103 days. Diet FM, containing only fish meal as protein source, was used as control treatment and compared to diet PV80, where a plant protein mix (pea protein concentrate and wheat gluten) was included to replace 80% of fish meal protein. Growth performance (FBW: 318.5g; SGR: 1.06%) and feed to gain ratio (0.79) of the fish were not affected by dietary treatment (p>0.05). Dry matter and protein ADCs, measured in vivo after stripping, resulted higher in fish fed the high vegetable protein diet relative to the fish meal one (p<0.05). Trout fed diet PV80 were characterised by higher agility index (2.02 vs 1.72, p<0.05), carcass yield (91.95 vs 91.18%, p<0.05), lower hepatosomatic inde..

EP-1412: Experience using a commercial software for patient in-vivo and pre-treatment quality assurance

n/

Stereotactic reirradiation for local failure of brain metastases following previous radiosurgery: Systematic review and meta-analysis

Introduction: Local failure (LF) following stereotactic radiosurgery (SRS) of brain metastases (BM) may be treated with a second course of SRS (SRS2), though this procedure may increase the risk of symptomatic radionecrosis (RN). Methods: A literature search was conducted according to PRISMA to identify studies reporting LF, overall survival (OS) and RN rates following SRS2. Meta-analysis was performed to identify predictors of RN. Results: Analysis included 11 studies (335 patients,389 metastases). Pooled 1-year LF was 24 %(CI95 % 19–30 %): heterogeneity was acceptable (I2 = 21.4 %). Median pooled OS was 14 months (Confidence Interval 95 %, CI95 % 8.8–22.0 months). Cumulative crude RN rate was 13 % (95 %CI 8 %–19 %), with acceptable heterogeneity (I2 = 40.3 %). Subgroup analysis showed higher RN incidence in studies with median patient age ≥59 years (13 % [95 %CI 8 %–19 %] vs 7 %[95 %CI 3 %–12 %], p = 0.004) and lower incidence following prior Whole Brain Radiotherapy (WBRT, 19 %[95 %CI 13 %–25 %] vs 7%[95 %CI 3 %–13 %], p = 0.004). Conclusions: SRS2 is an effective strategy for in-site recurrence of BM previously treated with SRS